GNS Healthcare Uses Causal AI to Discover Which Multiple Myeloma Patients Will Have Progression Free Survival Benefit from Stem Cell Treatments
Details of the Discovery Leveraging the Multiple Myeloma Research Foundation CoMMpass Study Presented at 59th Annual ASH Meeting CAMBRIDGE, Mass.– December 12, 2017 – GNS Healthcare (GNS), a leading precision medicine company, together with the Multiple Myeloma Research Foundation (MMRF), have discovered a biomarker that identifies which multiple myeloma patients will benefit from stem cell transplantation. […]
Genentech oncology collaboration with GNS featured in TechEmergence
October 11, 2017 by Jon Walker Genentech, a member of the Roche Group, this summer announced their own collaboration with Cambridge, MA-based GNS Healthcare. GNS Healthcare’s mission statement is to use the latest innovations in machine learning to turn biomedical data into solutions and treatments. This collaboration’s first focus will also be on oncology, just like the IBM/Pfizer deal. Genentech […]
GNS Healthcare Uncovers Novel Targets for Triple-Negative Breast Cancer Using Causal Machine Learning and Simulation Platform REFS™
New Gene Discoveries Published by the American Association for Cancer Research CAMBRIDGE, Mass. – May 31, 2017– Leading precision medicine company GNS Healthcare (GNS), today announced the discovery of novel targets, including TRIB1, which correlates with survival, progression, and metastasis in resistant breast cancer. The study, which was conducted at University of California, San Francisco, […]
Gregg’s Diabetes Identifies GNS as One of a Handful of Companies Focused on Market Access
The 21st Century Cures Act makes “Real World Evidence” a buzz word in pharma and payer circles, and justifiably so. For the uninitiated, “Real World Evidence” (RWE) is a term that has received much and attention and debate as a core component of the 21st Century Cures Act: a bill that received much press coverage […]
GNS Prominently Featured in BioCentury Cover Story on Use of Machine Learning by Pharma
Applying machine learning tools to drug R&D could usher in a new era of effective therapies targeting causative disease drivers, higher success rates in clinical trials and real world tools to manage adherence, prevent adverse events and reduce total healthcare costs. Download the complete article here.
Outsourcing Pharma Puts Spotlight on Power of Causality, Highlights GNS-Celgene Deal Licensing REFS
Celgene has made a second investment in a machine learning and simulation platform for applications across drug discovery, clinical development, and commercialization. Read the full story here.
Celgene Enters Into Service and License Arrangement for GNS Healthcare’s Causal Machine Learning Platform to Accelerate Value-Based and Precision Medicine Development
CAMBRIDGE, Mass. – November 29, 2016 – GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to massive and diverse data streams to better match drugs and other health interventions to individual patients, today announced that Celgene Corporation has entered into a service and license arrangement for the rights to […]
InformationWeek Healthcare: Big Data Helps Insurer Pinpoint At-Risk Patients
Aetna and GNS Healthcare use analytics to predict patients at risk for metabolic syndrome Analyzing big data can predict patients’ future risk of metabolic syndrome and allow individuals and clinicians to work together on preventative steps that save lives and money. While organizations have used a lot of big data projects to discern trends, a […]
Infographic: The Real World of Big Data
The benefits of Big Data are often spoken of in the future tense. The reality, however, is that Big Data is today – here and now – delivering on its many promises. See how companies, including GNS Healthcare and Aetna, are using Big Data to create business value today: The Real World of Big Data […]